Blue Whiting (Micromesistius poutassou) Protein Hydrolysates Increase GLP-1 Secretion and Proglucagon Production in STC-1 Cells Whilst Maintaining Caco-2/HT29-MTX Co-Culture Integrity

Mar Drugs. 2022 Jan 31;20(2):112. doi: 10.3390/md20020112.

Abstract

Inducing the feeling of fullness via the regulation of satiety hormones presents an effective method for reducing excess energy intake and, in turn, preventing the development of obesity. In this study, the ability of blue whiting soluble protein hydrolysates (BWSPHs) and simulated gastrointestinal digested (SGID) BWSPHs, to modulate the secretion and/or production of satiety hormones, such as glucagon-like peptide-1 (GLP-1), cholecystokinin (CCK) and peptide YY (PYY), was assessed in murine enteroendocrine STC-1 cells. All BWSPHs (BW-SPH-A to BW-SPH-F) (1.0% w/v dw) increased active GLP-1 secretion and proglucagon production in STC-1 cells compared to the basal control (Krebs-Ringer buffer) (p < 0.05). The signaling pathway activated for GLP-1 secretion was also assessed. A significant increase in intracellular calcium levels was observed after incubation with all BWSPHs (p < 0.05) compared with the control, although none of the BWSPHs altered intracellular cyclic adenosine monophosphate (cAMP) concentrations. The secretagogue effect of the leading hydrolysate was diminished after SGID. Neither pre- nor post-SGID hydrolysates affected epithelial barrier integrity or stimulated interleukin (IL)-6 secretion in differentiated Caco-2/HT-29MTX co-cultured cells. These results suggest a role for BWSPH-derived peptides in satiety activity; however, these peptides may need to be protected by some means to avoid loss of activity during gastrointestinal transit.

Keywords: GLP-1; STC-1; blue whiting; gut health; protein hydrolysates; satiety hormones.

MeSH terms

  • Animals
  • Caco-2 Cells
  • Cell Line
  • Coculture Techniques
  • Enteroendocrine Cells / drug effects
  • Enteroendocrine Cells / metabolism
  • Gadiformes / metabolism*
  • Glucagon-Like Peptide 1 / drug effects*
  • Glucagon-Like Peptide 1 / metabolism
  • HT29 Cells
  • Humans
  • Mice
  • Proglucagon / drug effects*
  • Proglucagon / metabolism
  • Protein Hydrolysates / isolation & purification
  • Protein Hydrolysates / pharmacology*

Substances

  • Protein Hydrolysates
  • Proglucagon
  • Glucagon-Like Peptide 1